Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duodenal Eubacterium hallii infusion in men with metabolic syndrome
NL-OMON48576Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2018
- Countries
- 1
01
Overview
Randomised, double-blind trial in cardiometabolic risk (CMR) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in duodenal Eubacterium hallii levels at 6 hours and Change in duodenal gene expression including FXR at 6 hours. Started Jan 2018; status: active, not recruiting.
02
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON48576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48576.